Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?

J Thorac Oncol. 2014 Jul;9(7):e49-e50. doi: 10.1097/JTO.0000000000000134.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics*
  • Aged
  • DNA, Neoplasm / blood*
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Male
  • Middle Aged
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors

Substances

  • DNA, Neoplasm
  • Protein Kinase Inhibitors
  • ErbB Receptors
  • Protein-Tyrosine Kinases